Winchester, MA, United States of America

Nathan Dowden

This inventor holds 4 USPTO granted patents and 8 published patent applications and 2 EPO patents. Top assignee: Rubius Therapeutics, Inc.. Active years: 2019-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nathan Dowden. Retrieved from https://idiyas.com/inventor/nathan-dowden

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 4 (Patent Applications = 8)

EPO Patents = 2 (Patent Applications = 7)

Average Co-Inventor Count = 10.0

ph-index = 3

Forward Citations = 15(Granted Patents)

Company Filing History:

4 out of 16

Rubius Therapeutics, Inc.

patents

Years Active: 2019-2020

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10716811 - Compositions and methods related to multimodal therapeutic cancer indications (2020-07-21),

2. 10568910 - Compositions and methods related to engineered erythroid cells comprising IL-15 (2020-02-25),

3. 10517897 - Methods related to engineered erythoid cells comprising 4-1BBL (2019-12-31),

4. 10456421 - Compositions and methods related to engineered erythoid cells comprising 4-1BBL (2019-10-29),

Title: Nathan Dowden: Innovator in Cancer Therapeutics

Introduction

Nathan Dowden is a prominent inventor based in Winchester, MA (US), known for his significant contributions to the field of cancer therapeutics. With a total of 4 patents, Dowden has focused on developing innovative solutions that enhance treatment options for cancer patients.

Latest Patents

Among his latest patents, Dowden has developed compositions and methods related to multimodal therapeutic cancer indications. This invention includes compositions and methods that provide and/or administer a plurality of agents functioning in a coordinated manner to deliver therapeutic benefits to subjects in need, particularly those diagnosed with cancer. Another notable patent involves engineered erythroid cells comprising IL-15, which also focuses on multimodal therapies aimed at treating cancer effectively.

Career Highlights

Nathan Dowden is currently associated with Rubius Therapeutics, Inc., where he continues to advance his research and innovations in cancer treatment. His work is characterized by a commitment to improving patient outcomes through the development of novel therapeutic strategies.

Collaborations

Dowden collaborates with esteemed colleagues such as Avak Kahvejian and Jordi Mata-Fink, contributing to a dynamic research environment that fosters innovation and discovery in the field of cancer therapeutics.

Conclusion

Nathan Dowden's work exemplifies the spirit of innovation in the medical field, particularly in cancer treatment. His patents and collaborations reflect a dedication to improving therapeutic options for patients, making a significant impact in the fight against cancer.

Profile summary based on public USPTO records.